Skip to main content
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. — Investor Relations & Filings

Ticker · NAMS ISIN · NL00150012K9 LEI · 984500B6549TF6E14D36 US Professional, scientific and technical activities
Open in API
Filings indexed 372 across all filing types
Latest filing 2025-08-13 Director's Dealing
Country NL Netherlands
Listing US NAMS

About NewAmsterdam Pharma Co N.V.

https://ir.newamsterdampharma.com/

NewAmsterdam Pharma Co N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases where currently approved treatments have not been sufficiently successful or well-tolerated. The company's lead product candidate is obicetrapib, an oral, low-dose, once-daily CETP inhibitor. It is being investigated as a therapy to lower low-density lipoprotein cholesterol (LDL-C) as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. The company aims to address the unmet need for a potent, cost-effective, and convenient LDL-lowering treatment. In addition to its dyslipidemia program, the company also explores treatments for other metabolic disorders.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-08-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 6, 2025. It announces the issuance of a press release containing corporate updates and financial results for the quarter ended June 30, 2025. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document length is 3825 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing the financial results itself. According to the rules, such a document announcing the initial quarterly financial results is classified as an Earnings Release (ER).
2025-08-06 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 30, 2025, by NewAmsterdam Pharma Company N.V. It announces the release of full data from a prespecified Alzheimer's disease biomarker analysis in a Phase 3 clinical trial and includes a press release and a presentation as exhibits. The document describes the event and the data presentation at a conference, and mentions a live webcast and conference call. It is a current report disclosing material events or corporate updates rather than a full financial report or earnings release. The content fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain financial statements or detailed financial analysis. It is not an earnings release, annual report, or other specific report type. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-07-30 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.